To see, to know, to heal .    

Declare the past,
diagnose the present,
foretell the future (Hippocrates)

Seeing is the
beginning

Milestones
Research
About us
Career

photonamic

The name photonamic consists of photo (= light) and dynamics and thus represents the field of activity of photonamic GmbH & Co. KG ("photonamic"). The effect of light on certain molecules is manifold and ultimately leads not only to coloration, but can also lead to fluorescence or initiation of chemical reactions.
Photonamic takes advantage of these dynamics of light by using a specific molecule that is metabolized into a photosensitizer in cells or in cell assemblies or in the body. Depending on the choice of wavelength, this can lead to a wide variety of effects triggered by the light. The use of light and the application of photosensitizers is not really a new principle, but has been known and researched for decades.
photonamic has set itself the goal of researching and developing these possibilities in a targeted manner in order to derive diverse applications from them. Unlike many other approaches, the molecule primarily used by photonamic is a precursor of the actual photosensitizer, which is metabolically converted into the light-excitable molecule and exhibits the corresponding photodyna-mic properties. The resulting fascinating applications in imaging and also therapy form the core of photonamic's activities.
Through numerous collaborations and projects with partner companies, academic institutions for clinical applicability and also with corresponding equipment companies for light sources, sensors and camera systems, the diversity of these technologies can be imagined.

TOP STORIES

‍"SBI Pharma to succeed Marketing Authorization of "Alabel® Oral 1.5g" from Nobelpharma"

SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao; hereinafter "SBI Pharma"), a subsidiary company of SBI Holdings, Inc. which conducts research and development pharmaceuticals, etc., utilizing 5-aminolevulinic acid(*) will succeed marketing authorization of "Alabel® Oral 1.5g," photodynamic diagnostic agent for malignant glioma, in Japan from Nobelpharma Co., Ltd. (Head office: Chuo-ku, Tokyo; Representative Director: Jin Shiomura; hereinafter "Nobelpharma") as of October 1st, 2024.

SBI Pharma and Nobelpharma have jointly conducted the clinical trial for obtaining the marketing authorization of Alabel in March 2013 of which Nobelpharma became marketing authorization holder based on a license from photonamic GmbH & Co. KG (Head office: Pinneberg, Germany, CEO: Ulrich Kosciessa, Ph.D.; hereinafter "photonamic"). Now SBI Pharma will succeed the marketing authorization of Alabel based on a license agreement with photonamic GmbH & Co. KG, a subsidiary company of SBI Holdings, Inc. After the transfer, SBI Pharma will promote the proper use and sales as a Marketing Authorization Holder and a Seller.

....more

"First Patient Enrolled in OVA-302 Study After FDA Orphan Designation for Gleolan®"....more

NEWS ARCHIVE

All press articles